Shudda, Cudda, Wudda: Reevaluating the Treatment Revolution After the Fall By David Barr "Six Years of Lost Data" David Barr revisits the changes to the federal when-to-start recommendations announced earlier this year and urges us to consider both the roots…
The Drug Development Pipeline, 2001 Development Terminated GW420867X/HBY1293 GlaxoSmithKline JAIDS 2000; also summer IAS meeting ALX40-4C Allelix Pharmaceuticals Formulation difficulties, lack of efficacy AMD3100 AnorMed Inc. Cardiac arrhythmias at high doses, lack of efficacy at low PD-178390 Parke-Davis Casualty of…
Model Physician/Patient Pair Are Latest to Feel the Fury of Fragile, Unforgiving Treatment Plan By David Barr "Data now exist which suggest that even HIV-specific immune function may be augmented with prolonged therapy, providing optimism that meaningful immune control might…
Antiretroviral Renegade Fights Fashion with Didanosine Duo, Betting His Future on Genetic Barriers By Mike Barr "Souped-Up Monotherapy" When it comes to the management of a fatal infection like HIV, it has been argued that self-experimentation seldom leads to knowledge…
The link between HLA types and HIV disease progression has been known for over a decade now from, among others, analyses of data from the Multi-Center AIDS Cohort (MACS). McMichael and colleagues have also documented CTL escape through the mutation…
Outrage, Indifference Greet Plans for Worldwide Treatment Agenda -- As Millions More Die By Mark Harrington "No Drugs in Time for Her" In April, Kofi Annan, the UN Secretary General, said it would take just $7-10 billion a year to…
Call for Poor Country Focus on Treatment, Care Programs Elicits Voice of Concern from Vaccine Outfit By Mark Harrington Price of Global Public Health HIV $4.06 billion TB $500 million Malaria $1.0 billion Add'l. infrastructure $440 million TOTAL, Yrs…
The Not So Accelerated Access Initiative By Mark Harrington In early April the World Health Organization (WHO) and the World Trade Organization (WTO) held a small, secretive meeting in Hsbjr, Norway, on "Differential Pricing and Financing of Essential Drugs." Initially,…
Roche’s Valganciclovir is Recommended for Approval On 27 February at the sad and lonely Gaithersburg Holiday Inn, the FDA’s Antiviral Drug Advisory Committee (ADAC) held a hearing to discuss Hoffmann-La Roche’s NDA for valganciclovir for the treatment of CMV retinitis…
Government Experts Roll Back the Big Guns, And Slither Away to Trenches ‘Inferences, hints and clues’ Mark Harrington writes, “As someone who’s spent the last twelve years of my life trying to encourage more and better AIDS research, and has…